{"success":true,"data":{"pressRelease":{"id":"129095","rtpr_id":"nBw1rrVKTa","ticker":"AZN","exchange":"LSE","all_tickers":["AZN"],"title":"TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints","author":"Business Wire","published_at":"2026-08-27T11:00:00.632Z","article_body":"TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis\nacross both co-primary and all key secondary endpoints\n\nStatistically significant and clinically meaningful disease and symptom\nimprovements compared to placebo maintained through week 52\n\nEfficacy in a third epithelial-driven inflammatory disease supports broad\npotential of TEZSPIRE\n\nPositive high-level results from the Phase III CROSSING trial in patients with\neosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s\nTEZSPIRE(®) (tezepelumab-ekko) demonstrated statistically significant and\nclinically meaningful improvements across both co-primary and all key\nsecondary endpoints at week 24, which were sustained through week 52 in both\ndoses tested. The co-primary endpoints were histologic remission and the\nfrequency and severity of dysphagia (difficulty swallowing) compared to\nplacebo. The safety profile of TEZSPIRE in the trial was generally consistent\nwith its approved indications.\n\nCROSSING is a randomized, double-blind trial that evaluated the efficacy and\nsafety of TEZSPIRE administered subcutaneously every four weeks compared to\nplacebo in adults and adolescents with symptomatic and uncontrolled EoE while\non maintenance therapy.(1) In the trial, the first co-primary endpoint,\nhistologic remission, was defined as having a low count of peak eosinophils in\nthe esophageal tissue.(1) The second co-primary endpoint, the frequency and\nseverity of dysphagia, was assessed using the patient-reported Dysphagia\nSymptom Questionnaire (DSQ) and measured as a mean change from baseline in DSQ\nscore.(1)\n\nEoE is a chronic and progressive epithelial-driven inflammatory disorder of\nthe esophagus affecting more than 470,000 people in the US, with the\nprevalence increasing five-fold since 2009.(2,3 )The inflammation of the\nesophagus can lead to dysphagia, food impaction and esophageal narrowing.(2\n)Nearly half of patients, including adolescents, do not achieve adequate\ndisease control with current first-line treatments, which include dietary\nrestriction, swallowed topical corticosteroids and proton pump\ninhibitors.(4-6) For patients, the risk of food moving slowly or becoming\nstuck can make daily meals difficult and stressful.(7)\n\nArjan Bredenoord, MD, Gastroenterologist and professor at the Amsterdam\nUniversity Medical Center, Amsterdam, The Netherlands, and primary\ninvestigator in the trial, said: “Despite the availability of first-line\ntherapies or dietary interventions, many patients with eosinophilic\nesophagitis still experience substantial burden, including difficulty\nswallowing food, and emotional and daily-life impacts of the disease. The\nimpressive results from the CROSSING trial sustained over 52 weeks demonstrate\nthat tezepelumab, taken every four weeks, could provide a new approach to\ntreating this disease, with the potential to help more patients achieve\nremission and symptom improvement.”\n\nSharon Barr, Executive Vice President, BioPharmaceuticals R&D said: “The\npositive results of the Phase III CROSSING trial reinforce our confidence in\nthe differentiated mechanism of action of TEZSPIRE, which has now demonstrated\nclinically meaningful efficacy in a third epithelial-driven inflammatory\ndisease. Epithelial science represents an important and rapidly evolving area\nin respiratory and immunology medicine, and we look forward to sharing these\nresults at an upcoming medical meeting and with regulatory authorities as\nquickly as possible.”\n\nFull results will be shared with regulatory authorities and the scientific\ncommunity at an upcoming medical meeting.\n\nTEZSPIRE is a first-in-class human monoclonal antibody that inhibits the\naction of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that\nsits at the top of multiple inflammatory cascades. TEZSPIRE is currently\napproved for the treatment of severe asthma in the US, EU, China, Japan and\nmore than 70 countries across the globe, and for the treatment of chronic\nrhinosinusitis with nasal polyps (CRSwNP) in the US, EU, China and Japan. The\nPhase III JOURNEY and EMBARK trials evaluating TEZSPIRE in chronic obstructive\npulmonary disease (COPD) are ongoing.(8,9)\n\nIMPORTANT SAFETY INFORMATION\n\nCONTRAINDICATIONS\n\nKnown hypersensitivity to tezepelumab-ekko or excipients.\n\nWARNINGS AND PRECAUTIONS\n\nHypersensitivity Reactions\n\nHypersensitivity reactions were observed in the clinical trials (eg, rash and\nallergic conjunctivitis) following the administration of TEZSPIRE.\nPostmarketing cases of anaphylaxis have been reported. These reactions can\noccur within hours of administration, but in some instances have a delayed\nonset (i.e., days). In the event of a hypersensitivity reaction, consider the\nbenefits and risks for the individual patient to determine whether to continue\nor discontinue treatment with TEZSPIRE.\n\nAcute Asthma Symptoms or Deteriorating Disease\n\nTEZSPIRE should not be used to treat acute asthma symptoms, acute\nexacerbations, acute bronchospasm, or status asthmaticus.\n\nAbrupt Reduction of Corticosteroid Dosage\n\nDo not discontinue systemic or inhaled corticosteroids abruptly upon\ninitiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if\nappropriate, should be gradual and performed under the direct supervision of a\nphysician. Reduction in corticosteroid dose may be associated with systemic\nwithdrawal symptoms and/or unmask conditions previously suppressed by systemic\ncorticosteroid therapy.\n\nParasitic (Helminth) Infection\n\nIt is unknown if TEZSPIRE will influence a patient’s response against\nhelminth infections. Treat patients with pre-existing helminth infections\nbefore initiating therapy with TEZSPIRE. If patients become infected while\nreceiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue\nTEZSPIRE until infection resolves.\n\nLive Attenuated Vaccines\n\nThe concomitant use of TEZSPIRE and live attenuated vaccines has not been\nevaluated. The use of live attenuated vaccines should be avoided in patients\nreceiving TEZSPIRE.\n\nADVERSE REACTIONS\n\nThe most common adverse reactions (incidence ≥ 3%) are:\n\n\n * Asthma: pharyngitis, arthralgia, and back pain.\n\n * Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory\ntract infection, epistaxis, pharyngitis, back pain, influenza, injection site\nreaction and arthralgia\n\nUSE IN SPECIFIC POPULATIONS\n\nThere are no available data on TEZSPIRE use in pregnant women to evaluate for\nany drug-associated risk of major birth defects, miscarriage, or other adverse\nmaternal or fetal outcomes. Placental transfer of monoclonal antibodies such\nas tezepelumab-ekko is greater during the third trimester of pregnancy;\ntherefore, potential effects on a fetus are likely to be greater during the\nthird trimester of pregnancy.\n\nINDICATION\n\nTEZSPIRE is indicated for:\n\n\n * the add-on maintenance treatment of adult and pediatric patients aged 12 years\nand older with severe asthma. TEZSPIRE is not indicated for the relief of\nacute bronchospasm or status asthmaticus\n\n * the add-on maintenance treatment of adult and pediatric patients aged 12 years\nand older with inadequately controlled chronic rhinosinusitis with nasal\npolyps (CRSwNP)\n\nPlease see accompanying full Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Prescribing+Information&index=1&md5=9f032b17c2b157ff984cd1d7a285e8d3)\n, including Patient Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_pi_med_guide_rendition__c.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Patient+Information&index=2&md5=873760b81f134b5c2748d06d632b0017)\nand Instructions for Use\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_pi_ifu_rendition__c.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Instructions+for+Use&index=3&md5=d479d62dfd77547c380226ba339071eb)\n.\n\nYou may report side effects related to AstraZeneca products.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus-aereporting.astrazeneca.com%2Fadverse-events.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=report+side+effects+related+to+AstraZeneca+products.&index=4&md5=5915fd7ba4aacf72d88b93510a66b2e2)\n\nNotes\n\nEosinophilic Esophagitis (EoE)\n\nEoE is a chronic and progressive epithelial-driven inflammatory disorder of\nthe esophagus with prevalence growing across the world.(2,3 )It is\ncharacterized by inflammation, remodeling and esophageal epithelial\ndysfunction.(2) Epithelial dysfunction and inflammation are important\ncharacteristics of EoE and impede the ability of the epithelium to act as a\nphysical and immunological barrier against the external environment.(2)\n\nThe most common symptoms of EoE include difficulty and pain when swallowing,\nfood becoming stuck in the esophagus (which may require emergency medical\ninterventions), nausea and vomiting, abdominal or chest pain, poor appetite\nand difficulty sleeping.(2,10,11) Many patients, including adolescents,\nexperience a substantial impact on their quality of life including significant\nanxiety related to swallowing and choking, depression, and decreased\nwork/school productivity.(12,13)\n\nPatients are often treated with proton pump inhibitors or swallowed topical\ncorticosteroids to manage inflammation.(2,4) Nearly half of patients with EoE\nwill not respond to standard first-line therapies or dietary treatment.(5,6\n)Existing treatment options, including those targeting downstream mediators,\nmay not fully address epithelial-driven inflammation.(14,15)\n\nCROSSING\n\nCROSSING is a randomized, double-blind, placebo-controlled, multi-center,\nparallel-group, Phase III trial designed to evaluate the efficacy and safety\nof TEZSPIRE administered subcutaneously every four weeks, compared to placebo\nin patients aged 12-80 years with symptomatic and histologically active\nEoE.(1) A total of 368 patients were randomized in a 1:1:1 ratio to receive\neither a low or high dose of TEZSPIRE or placebo.(1)\n\nThe co-primary endpoints analyzed at Week 24 were the proportion of patients\nwith histologic remission, defined as a peak esophageal eosinophil count less\nthan or equal to six eosinophils per high-power field, and mean changes from\nbaseline in the DSQ.(1) The peak eosinophil count is obtained when biopsies of\nthe tissue of the esophagus are examined under a microscope.(1) A count of 15\nor more peak eosinophils per high power microscopic field measured by\nesophageal biopsy is often the cutoff used to diagnose EoE.(16,17 )The DSQ\ncaptures the presence and severity of dysphagia symptoms in a daily diary with\na four-item patient-reported questionnaire; the score is calculated over\n14-day periods, ranging from zero to 84, with a higher score indicating more\nsevere dysphagia.(1)\n\nKey secondary endpoints assessed histologic remission and dysphagia symptoms\nat Week 52; changes in endoscopic disease features (EoE-EREFS) and histologic\nseverity and extent (EoE-HSS) at Weeks 24 and 52; as well as endoscopic\nresponse, inflammatory remission and total endoscopic remission at Week 52.(1)\n\nIn the trial, patients were allowed to remain on background medications for\nEoE, including proton pump inhibitors and swallowed topical corticosteroids,\nprovided that they were stable prior to entry and during the treatment\nperiod.(1)\n\nTezepelumab and TSLP\n\nTezepelumab is being developed by AstraZeneca in collaboration with Amgen as a\nfirst-in-class human monoclonal antibody that inhibits the action of TSLP, a\nkey epithelial cytokine that sits at the top of multiple inflammatory\ncascades.(18) TSLP is critical in the initiation and persistence of allergic,\neosinophilic and other types of epithelial-driven inflammation associated with\nsevere asthma, CRSwNP, COPD and EoE.(19-20)\n\nTSLP is released by the epithelium in response to environmental triggers.(18)\nAcross these disease states, the expression of TSLP is increased and\ncorrelates with disease severity.(18-22)\n\nTEZSPIRE is approved as a single-use pre-filled syringe and auto-injector for\nself-administration in the US, EU, China and Japan.( )Since 2021, more than\n100,000 patients have been treated with TEZSPIRE for severe asthma.(23)\n\nIn October 2021, TEZSPIRE was granted Orphan Drug Designation by the U.S. Food\nand Drug Administration (FDA) for the treatment of EoE.(24) Beyond EoE,\nTEZSPIRE is also being explored in Phase III trials in COPD.(8,9)\n\nAmgen Collaboration\n\nThe 2012 Collaboration Agreement between Amgen and AstraZeneca has been\namended and updated over time. For TEZSPIRE, both companies continue to share\ncosts and profits equally after payment by AstraZeneca of a mid-single-digit\ninventor royalty to Amgen. AstraZeneca continues to lead development and Amgen\ncontinues to lead manufacturing. All aspects of the collaboration are under\nthe oversight of joint governing bodies. Under the agreement, Amgen and\nAstraZeneca jointly commercialize TEZSPIRE in the US. Amgen records product\nsales in the US, with AZ recording its share of US profits as Alliance\nRevenue. Outside of the US, AstraZeneca records product sales.\n\nAstraZeneca in Respiratory & Immunology\n\nRespiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key\ndisease area and growth driver to the Company.\n\nAstraZeneca is an established leader in respiratory care with a 50-year\nheritage and a growing portfolio of medicines in immune-mediated diseases. The\nCompany is committed to addressing the vast unmet needs of these chronic,\noften debilitating, diseases with a pipeline and portfolio of inhaled\nmedicines, biologics and new modalities aimed at previously unreachable\nbiologic targets. Our ambition is to deliver life-changing medicines that help\neliminate COPD as a leading cause of death, eliminate asthma attacks and\nachieve clinical remission in immune-mediated diseases.\n\nAstraZeneca \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.astrazeneca.com%2F&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=AstraZeneca&index=5&md5=bea05e43b7ca0e9346b09b63c6267159)\n\nAstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical\ncompany that focuses on the discovery, development, and commercialization of\nprescription medicines in Oncology, Rare Disease, and BioPharmaceuticals,\nincluding Cardiovascular, Renal & Metabolism, and Respiratory &\nImmunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are\nsold in more than 125 countries and used by millions of patients worldwide.\nPlease visit astrazeneca-us.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.astrazeneca.com%2F&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=astrazeneca-us.com&index=6&md5=05fd617a9a9cc9e5b3d907342bd3ca22)\nand follow the Company on social media @AstraZeneca\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fastrazeneca&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=%40AstraZeneca&index=7&md5=c294f2d32f6f7ae5e17395103d785aa4)\n.\n\nReferences\n\n\n 1. ClinicalTrials.gov. Efficacy and Safety of Tezepelumab in Patients With\nEosinophilic Esophagitis (CROSSING). Available at: \nhttps://clinicaltrials.gov/study/NCT05583227\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05583227&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05583227&index=8&md5=f48c83d1c9294690559b609b21e17bee)\n\n. [Last accessed August 2026].\n\n 2. Biedermann L. & Straumann A. Mechanisms and clinical management of\neosinophilic oesophagitis: an overview. Nature Reviews Gastroenterol &\nHepatol. 2023;20(2):101-119.\n\n 3. Thel HL, et al. Prevalence and costs of eosinophilic esophagitis in the United\nStates. Clin Gastroenterol Hepatol. 2025;23(2):272-280.e8.\n\n 4. Hirano I, et al. AGA Institute and the Joint Task Force on Allergy-Immunology\nPractice Parameters clinical guidelines for the management of eosinophilic\nesophagitis. Gastroenterology. 2020;158(6):1776-1786.\n\n 5. Strauss AL, Falk GW. Refractory eosinophilic esophagitis: what to do when the\npatient has not responded to proton pump inhibitors, steroids and diet. Curr\nOpin Gastroenterol. 2022;38(4):395-401.\n\n 6. Lucendo AJ, et al. Efficacy of proton pump inhibitor drugs for inducing\nclinical and histologic remission in patients with symptomatic esophageal\neosinophilia: a systematic review and meta-analysis. Clin Gastroenterol\nHepatol. 2016; 14(1):13-22.e1.\n\n 7. Ho CN, et al. Patient experience with eosinophilic esophagitis symptoms and\nimpacts on daily life based on in-trial qualitative interviews. J Patient Rep\nOutcomes. 2025;9(1):3.\n\n 8. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of\nTezepelumab in Adult Participants With Moderate to Very Severe COPD\n(D5241C00007) (JOURNEY). Available at: \nhttps://clinicaltrials.gov/study/NCT06878261\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06878261&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06878261&index=9&md5=90a6fd89fd983d297a969f4d3cdfab58)\n\n. [Last accessed August 2026].\n\n 9. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of\nTezepelumab in Adult Participants With Moderate to Very Severe COPD\n(D5241C00006) (EMBARK). Available at: \nhttps://clinicaltrials.gov/study/NCT06883305\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06883305&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06883305&index=10&md5=73d8aeee65cfd1c7f9a2d6d74d2e0460)\n\n. [Last accessed August 2026].\n\n 10. Gold BD, et al. Health-Related Quality of Life and Perceived Stigma in\nEosinophilic Esophagitis: A Real-World, US, Web-Based Survey. Gastro Hep Adv.\n2024;3(8):1087-97.\n\n 11. MedlinePlus. Eosinophilic esophagitis. Bethesda (MD): National Library of\nMedicine (US). Available at: \nhttps://medlineplus.gov/eosinophilicesophagitis.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmedlineplus.gov%2Feosinophilicesophagitis.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fmedlineplus.gov%2Feosinophilicesophagitis.html&index=11&md5=f06f6bc29a0b316bfab8553d8b9823c9)\n\n. [Last accessed August 2026].\n\n 12. Taft TH, et al. Anxiety and depression in eosinophilic esophagitis: a scoping\nreview and recommendations for future research. J Asthma Allergy.\n2019;12:389–99.\n\n 13. Harris RF, et al. Psychosocial dysfunction in children and adolescents with\neosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2013;57:500–5.\n\n 14. Underwood B, et al. Breaking down the complex pathophysiology of eosinophilic\nesophagitis. Ann Allergy Asthma Immunol. 2023;130(1):28-39\n\n 15. Gautam R, et al. Eosinophilic esophagitis: mechanisms of disease and approach\nto treatment. Curr Allergy Asthma Rep. 2026;26:21.\n\n 16. Lucendo AJ, et al. British Society of Gastroenterology (BSG) and British\nSociety of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN)\njoint consensus guidelines on the diagnosis and management of eosinophilic\noesophagitis in children and adults. Gut. 2022;71(8):1459-1487.\n\n 17. Dellon ES, et al. ACG Clinical Guideline: Diagnosis and Management of\nEosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59.\n\n 18. Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory\nDisorders, and Cancer. Front Immunol. 2018;9:1595.\n\n 19. Calderon AA, et al. Targeting interleukin-33 and thymic stromal lymphopoietin\npathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev.\n2023;32(167):220144.\n\n 20. Nagarkar DR, et al. Thymic stromal lymphopoietin activity is increased in\nnasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol.\n2013;132(3):593-600.e12.\n\n 21. Ying, S, et al. Thymic stromal lymphopoietin expression is increased in\nasthmatic airways and correlates with expression of Th2-attracting chemokines\nand disease severity. J Immunol 2005;174:8183-8190.\n\n 22. Sherrill JD, et al. Preferential Secretion of Thymic Stromal Lymphopoietin\n(TSLP) by Terminally Differentiated Esophageal Epithelial Cells: Relevance to\nEosinophilic Esophagitis. PLoS One. 2016;11(2): e0148216.\n\n 23. AstraZeneca Data on File. 2025. REF-278452.\n\n 24. AstraZeneca press release. Tezepelumab granted Orphan Drug Designation in the\nUS for eosinophilic esophagitis. Available at: \nhttps://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2021%2Ftezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2021%2Ftezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html&index=12&md5=77fd3bd818f8a8ecfe7e4d34c3b3dada)\n\n. [Last accessed: August 2026].\n\nMatthew Bowden\n\nCompany Secretary\n\nAstraZeneca PLC\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260827018870/en/\n(https://www.businesswire.com/news/home/20260827018870/en/)\n\nMedia Inquiries \n\nFiona Cookson +1 212 814 3923\n\nLauren-Jey McCarthy +1 347 918 7001\n\nUS Media Mailbox: usmediateam@astrazeneca.com\n(mailto:usmediateam@astrazeneca.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw1rrVKTa","title":"TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints","author":"Business Wire","ticker":"AZN","created":"2026-08-27T11:00:00.632Z","tickers":["AZN"],"exchange":"LSE","article_body":"TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis\nacross both co-primary and all key secondary endpoints\n\nStatistically significant and clinically meaningful disease and symptom\nimprovements compared to placebo maintained through week 52\n\nEfficacy in a third epithelial-driven inflammatory disease supports broad\npotential of TEZSPIRE\n\nPositive high-level results from the Phase III CROSSING trial in patients with\neosinophilic esophagitis (EoE) showed that AstraZeneca and Amgen’s\nTEZSPIRE(®) (tezepelumab-ekko) demonstrated statistically significant and\nclinically meaningful improvements across both co-primary and all key\nsecondary endpoints at week 24, which were sustained through week 52 in both\ndoses tested. The co-primary endpoints were histologic remission and the\nfrequency and severity of dysphagia (difficulty swallowing) compared to\nplacebo. The safety profile of TEZSPIRE in the trial was generally consistent\nwith its approved indications.\n\nCROSSING is a randomized, double-blind trial that evaluated the efficacy and\nsafety of TEZSPIRE administered subcutaneously every four weeks compared to\nplacebo in adults and adolescents with symptomatic and uncontrolled EoE while\non maintenance therapy.(1) In the trial, the first co-primary endpoint,\nhistologic remission, was defined as having a low count of peak eosinophils in\nthe esophageal tissue.(1) The second co-primary endpoint, the frequency and\nseverity of dysphagia, was assessed using the patient-reported Dysphagia\nSymptom Questionnaire (DSQ) and measured as a mean change from baseline in DSQ\nscore.(1)\n\nEoE is a chronic and progressive epithelial-driven inflammatory disorder of\nthe esophagus affecting more than 470,000 people in the US, with the\nprevalence increasing five-fold since 2009.(2,3 )The inflammation of the\nesophagus can lead to dysphagia, food impaction and esophageal narrowing.(2\n)Nearly half of patients, including adolescents, do not achieve adequate\ndisease control with current first-line treatments, which include dietary\nrestriction, swallowed topical corticosteroids and proton pump\ninhibitors.(4-6) For patients, the risk of food moving slowly or becoming\nstuck can make daily meals difficult and stressful.(7)\n\nArjan Bredenoord, MD, Gastroenterologist and professor at the Amsterdam\nUniversity Medical Center, Amsterdam, The Netherlands, and primary\ninvestigator in the trial, said: “Despite the availability of first-line\ntherapies or dietary interventions, many patients with eosinophilic\nesophagitis still experience substantial burden, including difficulty\nswallowing food, and emotional and daily-life impacts of the disease. The\nimpressive results from the CROSSING trial sustained over 52 weeks demonstrate\nthat tezepelumab, taken every four weeks, could provide a new approach to\ntreating this disease, with the potential to help more patients achieve\nremission and symptom improvement.”\n\nSharon Barr, Executive Vice President, BioPharmaceuticals R&D said: “The\npositive results of the Phase III CROSSING trial reinforce our confidence in\nthe differentiated mechanism of action of TEZSPIRE, which has now demonstrated\nclinically meaningful efficacy in a third epithelial-driven inflammatory\ndisease. Epithelial science represents an important and rapidly evolving area\nin respiratory and immunology medicine, and we look forward to sharing these\nresults at an upcoming medical meeting and with regulatory authorities as\nquickly as possible.”\n\nFull results will be shared with regulatory authorities and the scientific\ncommunity at an upcoming medical meeting.\n\nTEZSPIRE is a first-in-class human monoclonal antibody that inhibits the\naction of thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that\nsits at the top of multiple inflammatory cascades. TEZSPIRE is currently\napproved for the treatment of severe asthma in the US, EU, China, Japan and\nmore than 70 countries across the globe, and for the treatment of chronic\nrhinosinusitis with nasal polyps (CRSwNP) in the US, EU, China and Japan. The\nPhase III JOURNEY and EMBARK trials evaluating TEZSPIRE in chronic obstructive\npulmonary disease (COPD) are ongoing.(8,9)\n\nIMPORTANT SAFETY INFORMATION\n\nCONTRAINDICATIONS\n\nKnown hypersensitivity to tezepelumab-ekko or excipients.\n\nWARNINGS AND PRECAUTIONS\n\nHypersensitivity Reactions\n\nHypersensitivity reactions were observed in the clinical trials (eg, rash and\nallergic conjunctivitis) following the administration of TEZSPIRE.\nPostmarketing cases of anaphylaxis have been reported. These reactions can\noccur within hours of administration, but in some instances have a delayed\nonset (i.e., days). In the event of a hypersensitivity reaction, consider the\nbenefits and risks for the individual patient to determine whether to continue\nor discontinue treatment with TEZSPIRE.\n\nAcute Asthma Symptoms or Deteriorating Disease\n\nTEZSPIRE should not be used to treat acute asthma symptoms, acute\nexacerbations, acute bronchospasm, or status asthmaticus.\n\nAbrupt Reduction of Corticosteroid Dosage\n\nDo not discontinue systemic or inhaled corticosteroids abruptly upon\ninitiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if\nappropriate, should be gradual and performed under the direct supervision of a\nphysician. Reduction in corticosteroid dose may be associated with systemic\nwithdrawal symptoms and/or unmask conditions previously suppressed by systemic\ncorticosteroid therapy.\n\nParasitic (Helminth) Infection\n\nIt is unknown if TEZSPIRE will influence a patient’s response against\nhelminth infections. Treat patients with pre-existing helminth infections\nbefore initiating therapy with TEZSPIRE. If patients become infected while\nreceiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue\nTEZSPIRE until infection resolves.\n\nLive Attenuated Vaccines\n\nThe concomitant use of TEZSPIRE and live attenuated vaccines has not been\nevaluated. The use of live attenuated vaccines should be avoided in patients\nreceiving TEZSPIRE.\n\nADVERSE REACTIONS\n\nThe most common adverse reactions (incidence ≥ 3%) are:\n\n\n * Asthma: pharyngitis, arthralgia, and back pain.\n\n * Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory\ntract infection, epistaxis, pharyngitis, back pain, influenza, injection site\nreaction and arthralgia\n\nUSE IN SPECIFIC POPULATIONS\n\nThere are no available data on TEZSPIRE use in pregnant women to evaluate for\nany drug-associated risk of major birth defects, miscarriage, or other adverse\nmaternal or fetal outcomes. Placental transfer of monoclonal antibodies such\nas tezepelumab-ekko is greater during the third trimester of pregnancy;\ntherefore, potential effects on a fetus are likely to be greater during the\nthird trimester of pregnancy.\n\nINDICATION\n\nTEZSPIRE is indicated for:\n\n\n * the add-on maintenance treatment of adult and pediatric patients aged 12 years\nand older with severe asthma. TEZSPIRE is not indicated for the relief of\nacute bronchospasm or status asthmaticus\n\n * the add-on maintenance treatment of adult and pediatric patients aged 12 years\nand older with inadequately controlled chronic rhinosinusitis with nasal\npolyps (CRSwNP)\n\nPlease see accompanying full Prescribing Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_viewable_rendition__v.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Prescribing+Information&index=1&md5=9f032b17c2b157ff984cd1d7a285e8d3)\n, including Patient Information\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_pi_med_guide_rendition__c.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Patient+Information&index=2&md5=873760b81f134b5c2748d06d632b0017)\nand Instructions for Use\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdrd9vrdh9yh09.cloudfront.net%2F50fd68b9-106b-4550-b5d0-12b045f8b184%2Fe306dc06-d580-4457-b15f-9f28545ad63a%2Fe306dc06-d580-4457-b15f-9f28545ad63a_pi_ifu_rendition__c.pdf&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=Instructions+for+Use&index=3&md5=d479d62dfd77547c380226ba339071eb)\n.\n\nYou may report side effects related to AstraZeneca products.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fus-aereporting.astrazeneca.com%2Fadverse-events.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=report+side+effects+related+to+AstraZeneca+products.&index=4&md5=5915fd7ba4aacf72d88b93510a66b2e2)\n\nNotes\n\nEosinophilic Esophagitis (EoE)\n\nEoE is a chronic and progressive epithelial-driven inflammatory disorder of\nthe esophagus with prevalence growing across the world.(2,3 )It is\ncharacterized by inflammation, remodeling and esophageal epithelial\ndysfunction.(2) Epithelial dysfunction and inflammation are important\ncharacteristics of EoE and impede the ability of the epithelium to act as a\nphysical and immunological barrier against the external environment.(2)\n\nThe most common symptoms of EoE include difficulty and pain when swallowing,\nfood becoming stuck in the esophagus (which may require emergency medical\ninterventions), nausea and vomiting, abdominal or chest pain, poor appetite\nand difficulty sleeping.(2,10,11) Many patients, including adolescents,\nexperience a substantial impact on their quality of life including significant\nanxiety related to swallowing and choking, depression, and decreased\nwork/school productivity.(12,13)\n\nPatients are often treated with proton pump inhibitors or swallowed topical\ncorticosteroids to manage inflammation.(2,4) Nearly half of patients with EoE\nwill not respond to standard first-line therapies or dietary treatment.(5,6\n)Existing treatment options, including those targeting downstream mediators,\nmay not fully address epithelial-driven inflammation.(14,15)\n\nCROSSING\n\nCROSSING is a randomized, double-blind, placebo-controlled, multi-center,\nparallel-group, Phase III trial designed to evaluate the efficacy and safety\nof TEZSPIRE administered subcutaneously every four weeks, compared to placebo\nin patients aged 12-80 years with symptomatic and histologically active\nEoE.(1) A total of 368 patients were randomized in a 1:1:1 ratio to receive\neither a low or high dose of TEZSPIRE or placebo.(1)\n\nThe co-primary endpoints analyzed at Week 24 were the proportion of patients\nwith histologic remission, defined as a peak esophageal eosinophil count less\nthan or equal to six eosinophils per high-power field, and mean changes from\nbaseline in the DSQ.(1) The peak eosinophil count is obtained when biopsies of\nthe tissue of the esophagus are examined under a microscope.(1) A count of 15\nor more peak eosinophils per high power microscopic field measured by\nesophageal biopsy is often the cutoff used to diagnose EoE.(16,17 )The DSQ\ncaptures the presence and severity of dysphagia symptoms in a daily diary with\na four-item patient-reported questionnaire; the score is calculated over\n14-day periods, ranging from zero to 84, with a higher score indicating more\nsevere dysphagia.(1)\n\nKey secondary endpoints assessed histologic remission and dysphagia symptoms\nat Week 52; changes in endoscopic disease features (EoE-EREFS) and histologic\nseverity and extent (EoE-HSS) at Weeks 24 and 52; as well as endoscopic\nresponse, inflammatory remission and total endoscopic remission at Week 52.(1)\n\nIn the trial, patients were allowed to remain on background medications for\nEoE, including proton pump inhibitors and swallowed topical corticosteroids,\nprovided that they were stable prior to entry and during the treatment\nperiod.(1)\n\nTezepelumab and TSLP\n\nTezepelumab is being developed by AstraZeneca in collaboration with Amgen as a\nfirst-in-class human monoclonal antibody that inhibits the action of TSLP, a\nkey epithelial cytokine that sits at the top of multiple inflammatory\ncascades.(18) TSLP is critical in the initiation and persistence of allergic,\neosinophilic and other types of epithelial-driven inflammation associated with\nsevere asthma, CRSwNP, COPD and EoE.(19-20)\n\nTSLP is released by the epithelium in response to environmental triggers.(18)\nAcross these disease states, the expression of TSLP is increased and\ncorrelates with disease severity.(18-22)\n\nTEZSPIRE is approved as a single-use pre-filled syringe and auto-injector for\nself-administration in the US, EU, China and Japan.( )Since 2021, more than\n100,000 patients have been treated with TEZSPIRE for severe asthma.(23)\n\nIn October 2021, TEZSPIRE was granted Orphan Drug Designation by the U.S. Food\nand Drug Administration (FDA) for the treatment of EoE.(24) Beyond EoE,\nTEZSPIRE is also being explored in Phase III trials in COPD.(8,9)\n\nAmgen Collaboration\n\nThe 2012 Collaboration Agreement between Amgen and AstraZeneca has been\namended and updated over time. For TEZSPIRE, both companies continue to share\ncosts and profits equally after payment by AstraZeneca of a mid-single-digit\ninventor royalty to Amgen. AstraZeneca continues to lead development and Amgen\ncontinues to lead manufacturing. All aspects of the collaboration are under\nthe oversight of joint governing bodies. Under the agreement, Amgen and\nAstraZeneca jointly commercialize TEZSPIRE in the US. Amgen records product\nsales in the US, with AZ recording its share of US profits as Alliance\nRevenue. Outside of the US, AstraZeneca records product sales.\n\nAstraZeneca in Respiratory & Immunology\n\nRespiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key\ndisease area and growth driver to the Company.\n\nAstraZeneca is an established leader in respiratory care with a 50-year\nheritage and a growing portfolio of medicines in immune-mediated diseases. The\nCompany is committed to addressing the vast unmet needs of these chronic,\noften debilitating, diseases with a pipeline and portfolio of inhaled\nmedicines, biologics and new modalities aimed at previously unreachable\nbiologic targets. Our ambition is to deliver life-changing medicines that help\neliminate COPD as a leading cause of death, eliminate asthma attacks and\nachieve clinical remission in immune-mediated diseases.\n\nAstraZeneca \n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.astrazeneca.com%2F&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=AstraZeneca&index=5&md5=bea05e43b7ca0e9346b09b63c6267159)\n\nAstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical\ncompany that focuses on the discovery, development, and commercialization of\nprescription medicines in Oncology, Rare Disease, and BioPharmaceuticals,\nincluding Cardiovascular, Renal & Metabolism, and Respiratory &\nImmunology. Based in Cambridge, UK, AstraZeneca’s innovative medicines are\nsold in more than 125 countries and used by millions of patients worldwide.\nPlease visit astrazeneca-us.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.astrazeneca.com%2F&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=astrazeneca-us.com&index=6&md5=05fd617a9a9cc9e5b3d907342bd3ca22)\nand follow the Company on social media @AstraZeneca\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fastrazeneca&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=%40AstraZeneca&index=7&md5=c294f2d32f6f7ae5e17395103d785aa4)\n.\n\nReferences\n\n\n 1. ClinicalTrials.gov. Efficacy and Safety of Tezepelumab in Patients With\nEosinophilic Esophagitis (CROSSING). Available at: \nhttps://clinicaltrials.gov/study/NCT05583227\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05583227&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05583227&index=8&md5=f48c83d1c9294690559b609b21e17bee)\n\n. [Last accessed August 2026].\n\n 2. Biedermann L. & Straumann A. Mechanisms and clinical management of\neosinophilic oesophagitis: an overview. Nature Reviews Gastroenterol &\nHepatol. 2023;20(2):101-119.\n\n 3. Thel HL, et al. Prevalence and costs of eosinophilic esophagitis in the United\nStates. Clin Gastroenterol Hepatol. 2025;23(2):272-280.e8.\n\n 4. Hirano I, et al. AGA Institute and the Joint Task Force on Allergy-Immunology\nPractice Parameters clinical guidelines for the management of eosinophilic\nesophagitis. Gastroenterology. 2020;158(6):1776-1786.\n\n 5. Strauss AL, Falk GW. Refractory eosinophilic esophagitis: what to do when the\npatient has not responded to proton pump inhibitors, steroids and diet. Curr\nOpin Gastroenterol. 2022;38(4):395-401.\n\n 6. Lucendo AJ, et al. Efficacy of proton pump inhibitor drugs for inducing\nclinical and histologic remission in patients with symptomatic esophageal\neosinophilia: a systematic review and meta-analysis. Clin Gastroenterol\nHepatol. 2016; 14(1):13-22.e1.\n\n 7. Ho CN, et al. Patient experience with eosinophilic esophagitis symptoms and\nimpacts on daily life based on in-trial qualitative interviews. J Patient Rep\nOutcomes. 2025;9(1):3.\n\n 8. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of\nTezepelumab in Adult Participants With Moderate to Very Severe COPD\n(D5241C00007) (JOURNEY). Available at: \nhttps://clinicaltrials.gov/study/NCT06878261\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06878261&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06878261&index=9&md5=90a6fd89fd983d297a969f4d3cdfab58)\n\n. [Last accessed August 2026].\n\n 9. ClinicalTrials.gov. A Study to Investigate the Efficacy and Safety of\nTezepelumab in Adult Participants With Moderate to Very Severe COPD\n(D5241C00006) (EMBARK). Available at: \nhttps://clinicaltrials.gov/study/NCT06883305\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06883305&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06883305&index=10&md5=73d8aeee65cfd1c7f9a2d6d74d2e0460)\n\n. [Last accessed August 2026].\n\n 10. Gold BD, et al. Health-Related Quality of Life and Perceived Stigma in\nEosinophilic Esophagitis: A Real-World, US, Web-Based Survey. Gastro Hep Adv.\n2024;3(8):1087-97.\n\n 11. MedlinePlus. Eosinophilic esophagitis. Bethesda (MD): National Library of\nMedicine (US). Available at: \nhttps://medlineplus.gov/eosinophilicesophagitis.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fmedlineplus.gov%2Feosinophilicesophagitis.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fmedlineplus.gov%2Feosinophilicesophagitis.html&index=11&md5=f06f6bc29a0b316bfab8553d8b9823c9)\n\n. [Last accessed August 2026].\n\n 12. Taft TH, et al. Anxiety and depression in eosinophilic esophagitis: a scoping\nreview and recommendations for future research. J Asthma Allergy.\n2019;12:389–99.\n\n 13. Harris RF, et al. Psychosocial dysfunction in children and adolescents with\neosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2013;57:500–5.\n\n 14. Underwood B, et al. Breaking down the complex pathophysiology of eosinophilic\nesophagitis. Ann Allergy Asthma Immunol. 2023;130(1):28-39\n\n 15. Gautam R, et al. Eosinophilic esophagitis: mechanisms of disease and approach\nto treatment. Curr Allergy Asthma Rep. 2026;26:21.\n\n 16. Lucendo AJ, et al. British Society of Gastroenterology (BSG) and British\nSociety of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN)\njoint consensus guidelines on the diagnosis and management of eosinophilic\noesophagitis in children and adults. Gut. 2022;71(8):1459-1487.\n\n 17. Dellon ES, et al. ACG Clinical Guideline: Diagnosis and Management of\nEosinophilic Esophagitis. Am J Gastroenterol. 2025;120(1):31-59.\n\n 18. Varricchi G, et al. Thymic Stromal Lymphopoietin Isoforms, Inflammatory\nDisorders, and Cancer. Front Immunol. 2018;9:1595.\n\n 19. Calderon AA, et al. Targeting interleukin-33 and thymic stromal lymphopoietin\npathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev.\n2023;32(167):220144.\n\n 20. Nagarkar DR, et al. Thymic stromal lymphopoietin activity is increased in\nnasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol.\n2013;132(3):593-600.e12.\n\n 21. Ying, S, et al. Thymic stromal lymphopoietin expression is increased in\nasthmatic airways and correlates with expression of Th2-attracting chemokines\nand disease severity. J Immunol 2005;174:8183-8190.\n\n 22. Sherrill JD, et al. Preferential Secretion of Thymic Stromal Lymphopoietin\n(TSLP) by Terminally Differentiated Esophageal Epithelial Cells: Relevance to\nEosinophilic Esophagitis. PLoS One. 2016;11(2): e0148216.\n\n 23. AstraZeneca Data on File. 2025. REF-278452.\n\n 24. AstraZeneca press release. Tezepelumab granted Orphan Drug Designation in the\nUS for eosinophilic esophagitis. Available at: \nhttps://www.astrazeneca.com/media-centre/press-releases/2021/tezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2021%2Ftezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html&esheet=54595500&newsitemid=20260827018870&lan=en-US&anchor=https%3A%2F%2Fwww.astrazeneca.com%2Fmedia-centre%2Fpress-releases%2F2021%2Ftezepelumab-granted-orphan-drug-designation-in-the-us-for-eosinophilic-esophagitis.html&index=12&md5=77fd3bd818f8a8ecfe7e4d34c3b3dada)\n\n. [Last accessed: August 2026].\n\nMatthew Bowden\n\nCompany Secretary\n\nAstraZeneca PLC\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260827018870/en/\n(https://www.businesswire.com/news/home/20260827018870/en/)\n\nMedia Inquiries \n\nFiona Cookson +1 212 814 3923\n\nLauren-Jey McCarthy +1 347 918 7001\n\nUS Media Mailbox: usmediateam@astrazeneca.com\n(mailto:usmediateam@astrazeneca.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-08-27T11:00:00.80123607Z","server_sent_at_ms":1787828400801},"received_at":"2026-08-27T11:00:00.852Z","source_url":"https://www.businesswire.com/news/home/20260827018870/en/"},"analysis":{"id":"118010","press_release_id":"129095","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"clinical_trial","narrative":"AstraZeneca and Amgen’s TEZSPIRE met both co-primary endpoints and all key secondary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE), demonstrating significant improvements in histologic remission and dysphagia symptoms.\n\nThe positive efficacy results were sustained through 52 weeks, and the safety profile remained consistent with the drug’s existing approved indications for severe asthma and nasal polyps.\n\nEoE affects more than 470,000 people in the US, and the success in this third epithelial-driven inflammatory disease supports the broad potential of TEZSPIRE.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"TEZSPIRE posts a clean Phase III sweep in eosinophilic esophagitis, setting the stage for a major label expansion."},"keyFigures":{"drugName":"TEZSPIRE (tezepelumab-ekko)","phaseOfTrial":"Phase III","customDimensions":{"patients_enrolled":368,"affected_population_us":"more than 470,000","prevalence_increase_since_2009":"five-fold"}},"quotedText":"The positive results of the Phase III CROSSING trial reinforce our confidence in the differentiated mechanism of action of TEZSPIRE, which has now demonstrated clinically meaningful efficacy in a third epithelial-driven inflammatory disease.","namedEntities":{"people":[{"name":"Arjan Bredenoord","role":"Primary Investigator and Professor, Amsterdam University Medical Center"},{"name":"Sharon Barr","role":"Executive Vice President, BioPharmaceuticals R&D"}],"products":["TEZSPIRE","tezepelumab-ekko"],"companies":[{"name":"AstraZeneca","ticker":"AZN"},{"name":"Amgen","ticker":"AMGN","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":4,"reasoning":"Phase III trial success for TEZSPIRE in a new indication (eosinophilic esophagitis) with statistically significant and clinically meaningful improvements on all primary and secondary endpoints, significantly expanding the drug's commercial potential."},"tickerRelevance":{"others":[{"ticker":"AMGN","relevance":"partner"}],"primary":"AZN"},"globalImportance":55,"audienceRelevance":65,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mega-cap","eventGravity":"phase_3_success","sectorWeight":"pharma","householdBrandBoost":true}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":4,"narrative":"AstraZeneca and Amgen’s TEZSPIRE met both co-primary endpoints and all key secondary endpoints in the Phase III CROSSING trial for eosinophilic esophagitis (EoE), demonstrating significant improvements in histologic remission and dysphagia symptoms.\n\nThe positive efficacy results were sustained through 52 weeks, and the safety profile remained consistent with the drug’s existing approved indications for severe asthma and nasal polyps.\n\nEoE affects more than 470,000 people in the US, and the success in this third epithelial-driven inflammatory disease supports the broad potential of TEZSPIRE.","key_figures":{"drugName":"TEZSPIRE (tezepelumab-ekko)","phaseOfTrial":"Phase III","customDimensions":{"patients_enrolled":368,"affected_population_us":"more than 470,000","prevalence_increase_since_2009":"five-fold"}},"named_entities":{"people":[{"name":"Arjan Bredenoord","role":"Primary Investigator and Professor, Amsterdam University Medical Center"},{"name":"Sharon Barr","role":"Executive Vice President, BioPharmaceuticals R&D"}],"products":["TEZSPIRE","tezepelumab-ekko"],"companies":[{"name":"AstraZeneca","ticker":"AZN"},{"name":"Amgen","ticker":"AMGN","relationship":"partner"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-27T11:08:36.112Z","global_importance":55,"audience_relevance":65,"importance_components":{"tickerTier":"mega-cap","eventGravity":"phase_3_success","sectorWeight":"pharma","householdBrandBoost":true}},"durationMs":83777,"modelName":"glm-4.7"}}